Recognition of Carbohydrate by Major Histocompatibility Complex Class I–restricted, Glycopeptide-specific Cytotoxic T Lymphocytes

By John S. Haurum,* Gemma Arsequell,† Annemarie C. Lellouch,‡ Simon Y. C. Wong,‡ Raymond A. Dwek,‡ Andrew J. McMichael,* and Tim Elliott*

From the *Molecular Immunology Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU; and the †Glyobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK

Summary

Cytotoxic T cells (CTL) recognize short peptide epitopes presented by class I glycoproteins encoded by the major histocompatibility complex (MHC). It is not yet known whether peptides containing posttranslationally modified amino acids can also be recognized by CTL. To address this issue, we have studied the immunogenicity and recognition of a glycopeptide carrying an O-linked N-acetylglucosamine (GlcNAc) monosaccharide-substituted serine residue. This posttranslational modification is catalyzed by a recently described cytosolic glycosyltransferase. We show that glycosylation does not affect peptide binding to MHC class I and that glycopeptides can elicit a strong CTL response that is glycopeptide specific. Furthermore, glycopeptide recognition by cytotoxic T cells is dependent on the chemical structure of the glycan as well as its position within the peptide.

T lymphocytes recognize peptide antigens as they are presented on the cell surface by polymorphic proteins encoded in the MHC class I or II. Class I MHC presents peptide fragments of intracellular synthesized protein, whereas class II MHC predominantly presents peptide fragments of extracellular proteins that have been degraded in the endocytic compartment (1). The allelic specificity of peptide binding to MHC is governed by pockets in the MHC binding groove that confer the preferred binding of certain amino acid residues within an allele-specific motif (2).

All natural T cell antigens identified to date consist of peptides with unmodified amino acid side chains. However, it is not known whether some of the posttranslational modifications that occur on proteins in vivo contribute to the recognition of peptide antigens by T cells. Thus, it is not known whether sulfated, phosphorylated, carboxylated, or glycosylated peptides can be selected for presentation by MHC with the posttranslational modification intact.

Studies on the recognition by CTLs of peptides haptenated with trinitrophenyl have demonstrated that T cells will specifically recognize chemically modified peptide antigens (3). It is therefore possible that peptides carrying natural posttranslational modifications, such as glycosylation, might similarly be recognized by T cells.

Several different types of protein glycosylation are known including the N-linked glycosylation of asparagine and O-linked glycosylation of serine and threonine occurring in the endoplasmic reticulum (ER) and Golgi apparatus. In addition, a novel O-linked glycosylation, occurring almost exclusively on nuclear and cytosolic proteins, has been described (4). This glycosylation is characterized by substitution of serines or threonines with single O-β-linked N-acetylgalactosamine (GalNAc) residues catalyzed by a cytosolic N-acetylgalactosaminyl transferase (reviewed in reference 5).

Since peptide fragments of cytosolic and nuclear proteins are the preferred substrates for antigen presentation by class I MHC, it is possible that glycopeptides derived from O-GlcNAc substituted cytosolic proteins could enter the class I presentation pathway. When bound to MHC class I, the O-β-GlcNAc modification on peptides could then be presented in such a way as to be specifically recognized by T cell receptors.

Here we report for the first time the efficient binding to class I MHC (H-2Kb and H-2Dd) of a synthetic glycopeptide carrying this naturally occurring O-linked GlcNAc and its carbohydrate-specific recognition by CTL.

Materials and Methods

Reagents and Antibodies. Fluorenylmethoxycarbonyl (Fmoc) amino acids and resins for the synthesis of peptides were purchased from Zinsser (Maidenhead, UK) and Novabiochem AG (Nottingham, UK). IMDM was from GIBCO, Ltd. (Glasgow, Scotland) and FCS from Seralab (Crawley Down, UK). The cell line RMA-S is a Rauscher virus–transformed murine T cell line that has a defective TAP 2 gene encoding the peptide

739 J. Exp. Med. © The Rockefeller University Press • 0022-1007/94/08/0739/06 $2.00
Volume 180 August 1994 739–744
transporter associated with antigen presentation (TAP) (6). A second, human TAP-defective cell line T2 (7), transfected with H2-Kb and H2-Dd, was maintained as described previously. C57BL/6 mice were obtained from Harlan Olac, Ltd. (Bicester, UK). Antibodies were purified from culture supernatant by affinity chromatography on protein-A Sepharose (Sigma Chemical Co., Poole, UK). The mAb Y3 recognizes a conformational epitope on the α1 and α2 domains of K3 (8) and mAb B22.249 recognizes a conformational epitope on the α1 domain of D9 (9).

Peptide Synthesis. The Sendai virus nucleoprotein (10, 11) wild-type (wt) peptide (FAPGNYPAL); amino acids are referred to by the single letter code) and the analogue K3 (FAPSNYPAL) were synthesized manually on Wang resin using conventional Fmoc chemistry. The solid phase synthesis, purification, and characterization of the glycopeptides K3-O-GlcNAc [FAPS (O-β-GlcNAc) NYPAL], K3-O-N-acetyl-D-galactosamine (GalNAc) [FAPS (O-α-GalNAc) NYPAL], and K1-N-GlcNAc [FAPGN (N-β-GlcNAc) YSAL] will be reported elsewhere (Arsequell, G., A. C. Lellouch, S. Y. Wong, J. S. Hanrum, T. Elliott, and R. A. Dwek, manuscript in preparation). Briefly, three glycosyl amino acids were synthesized as building blocks for solid-phase glycopeptide synthesis. FmocSer (β-β-GlcNAc) OH was prepared by glycosylation of FmocSerOH with per-acetylated (p)GlcNAc using boron trifluoride etherate catalysis. Glycosylation of Fmoc Serine pentafluorophenyl ester (FmocSerOpfp) with α-α-GalN3Br (obtained from n-Galactal [10]) using silver triflate as a catalyst afforded FmocSer(β-α-GalN3)Opfp. A coupling reaction between Fmoc aspartic t-butyl ester (FmocAspO BU) and the glycosylamine of GlcNAc, followed by acetylation with acetic anhydride and cleavage of the BU ester with TFA yielded FmocAsn (β-pGalN3)NacOH. The building blocks were purified and characterized before incorporation into the solid phase glycopeptide synthesis by a standard Fmoc protocol using FmocLeu derivatized Wang resin with benzotriazol-1-y1-oxy-triptyrrolidino-phosphonium hexafluoroacetic acid (PyBOP) as an activating agent (except with the Opfp derivative which needed no further activation). In the case of FmocSer (α-pGalN3) Opfp, thioacetic acid was used to convert the azido group to the N-acetyl group while the peptide was still resin bound (11). The peptides were cleaved from the resin using TFA/H2O, purified by reverse phase HPLC to greater than 99% purity, and deacetylated using a catalytic amount of sodium methoxide in absolute methanol, followed by repurification by HPLC. The peptides were characterized by proton nuclear magnetic resonance, amino acid analysis, hexosamine analysis (in the case of glycopeptides), and laser desorption mass spectrometry. Amino acid and hexose contents were as expected, as were the parent ions of each compound. Sterile filtered stock solutions of peptides (1–4 mg/ml in PBS) were stored at −70°C.

Assembly Assays for Peptide Binding to MHC. Assembly assays for binding of the synthetic peptides to Kb and Dd molecules metabolically labeled with 35S methionine were carried out essentially as described previously (12). This assay is based on the peptide-dependent stabilization of Kb and Dd after lysis of the peptide transporter (TAP 2)–deficient cell line RMA-S and the detection by immunoprecipitation with the conformation-specific antibodies Y3 and B22, respectively. Peptide binding was quantified by densitometry of the heavy chain band of autoradiographs after SDS-PAGE. Optical density was plotted against peptide concentration.

Establishment of CTL. C57BL/6 mice were immunized intraperitoneally with 100 μg s.c. of peptides K3 or K3-O-GlcNAc in incomplete Freund's adjuvant. Antipeptide CTL were stimulated in vitro on day 7 as described by Stauss et al. (13). RMA-S cells were cultured overnight at 25°C to induce high surface expression of (empty) Kb and Dd molecules (14) before pulsing for 2–4 h with 30 μM of the relevant peptide at 25°C and subsequent irradiation (7,000 rad). After washing, 2 × 106 peptide-pulsed RMA-S cells were used to stimulate 8 × 105 spleen cells from immunized animals per well in 24-well plates in basic medium (IMDM containing 10% FCS, with addition of penicillin, streptomycin, glutamine, and 5 × 10−5 M 2-mercaptoethanol), and peptides were added to the cultures (final concentration 30 μM). After 7 d, cells were restimulated with 2 × 105 irradiated C57BL/6 spleen cells/well and 5 μM peptide at a stimulator/responder ratio of 3:1 in complete medium (basic medium with 10% Con A supernatant). Thereafter, the CTL lines were restimulated weekly as above.

Cloning of T Cells. CTL lines against K3 and K3-O-GlcNAc were cloned in 96-well plates by limiting dilution on irradiated peptide pulsed syngeneic spleen cells (2.5 × 105/well) and temperature-induced peptide pulsed RMA-S cells (105/well) in 100 μl complete medium. Another 100 μl complete medium were added to each well on day 4 and good growing clones were transferred onto fresh feeder cells in 48-well plates on days 10–14.

CTL Assays. The peptide transporter–deficient cell line T2 transfected with Dd or K3 (T2-Dd or T2-K3), respectively, were used as target cells conventional CTL assays.

Results and Discussion

The peptides used in this investigation (Fig. 1) were analogues of the CTL epitope FAPGNYPAL from Sendai virus nucleoprotein (15). This sequence was chosen because it contains both a Dd (xxxxxNxxxL) and a Kb (xxxxxYxxL) binding motif (16, 17), allowing us to induce T cell responses to a single peptide presented by two different restriction elements. Also, a crystal structure of the peptide FAPGNYPAL in complex with K3 is available (18), enabling us to choose positions for carbohydrate modifications most likely to point out of the groove and interact with the TCR. The wt peptide as well as the analogue K3 and its O-glycosylated counterpart K3-O-GlcNAc were synthesized and tested for their ability to bind Kb and Dd. Fig. 2 shows that K3-O-GlcNAc bound to both Kb and Dd as efficiently as the wt peptide, when tested in the class I MHC RMA-S assembly assay, with half maximal binding at peptide concentrations of 60 nM for Kb and 12 nM for Dd compared with 90 and 12 nM for wt, respectively. Similarly, the non-glycosylated K3 bound well to both Kb and Dd with half maximal binding at peptide concentrations of 160 and 22 nM, respectively. It is interesting to note, that in a previous study, N-glycosylation of a class II-binding peptide (19) led to greatly reduced binding, regardless of the position of the modification within the MHC binding region of the peptide.

Having confirmed the efficient binding to Kb and Dd, K3 and K3-O-GlcNAc were used to generate CTL. After 2 in vitro stimulations, the peptide specificity and MHC restriction of CTL lines were tested in standard 51Cr release assays using peptide pulsed T2-Kb and T2-Dd as target cells. In addition, lines were cloned by limiting dilution in order to analyze the bulk response of each line at the clonal level. We derived nine CTL clones specific for K3 and 5 for K3-O-GlcNAc.

Immunization and restimulation with K3-O-GlcNAc gave rise to a CTL line with a high degree of specificity for the
glycosylated peptide with only marginal crossreactivity toward the nonglycosylated K3. Both K\(^b\)- and D\(^b\)-restricted responses were generated (Fig. 3). Analysis of CTL clones derived from this line showed that this was not due to crossreactivity between the restriction elements, but instead to the presence of both K\(^b\)- and D\(^b\)-restricted clones specific for K3-O-GlcNAc (Fig. 4, a and b). All of the five clones derived from CTL lines induced with K3-O-GlcNAc were specific for the glycopeptide, regardless of restriction element.

Similarly, immunization with the nonglycosylated counterpart K3 gave rise to lines specific for that peptide and with little crossreactivity with the glycosylated K3-O-GlcNAc.
by limiting dilution were tested in CTL assays against T2-Kb binding at 200 nM but was not recognized by any of the cell clones against peptides K3-O-GlcNAc (a and b) or K3 (c) obtained NYPAL is considered an anchor residue required for efficient was also tested against K1-N-GlcNAc carries an N-linked GlcNAc residue at position 5 (as well as a P to S substitution at position 7). K1-N-GlcNAc was also shown to bind efficiently to Kb with half maximal binding >10 nM) but not Kb (half maximal binding 200 nM). This peptide was also not recognized by any K3-O-GlcNAc-specific Db-restricted clones (data not shown).

In a separate set of experiments, CTL lines raised against K1-N-GlcNAc only displayed reactivity towards T2-Kb prepulsed with K1-N-GlcNAc, but not when prepulsed with K3-O-GlcNAc, or a nonglycosylated analogue, or when using T2-Db as targets (data not shown).

Other groups have raised MHC class II-restricted T cells to glycopeptides (19, 20). These studies showed, however, that potent immunogenicity was only retained when peptides were glycosylated outside the MHC binding region of the peptide. In one of these studies T cells generated to glycopeptides of high immunogenicity crossed-reacted with the nonglycosylated peptide (19); whereas in another study T cell hybridomas were generated that reacted preferentially with glycosylated peptide but at the same time showed equal reactivity towards dramatically different NH2-terminal glycosylations (20). Furthermore, T cells generated to the nonglycosylated peptide reacted equally well, or better, towards the NH2-terminally substituted glycopeptide.

We have demonstrated that a class I MHC binding peptide can be modified by O-glycosylation within the MHC binding region without affecting its binding to MHC class I. The resulting peptides are highly immunogenic, and elicit carbohydrate-specific, MHC-restricted, antiglycopeptide CTL. Furthermore, the O-β-linked GlcNAc substitution used in the present study is the first example of T cell recognition of a naturally occurring type of glycosylation. Proteins carrying this glycosylation which have been identified to date include RNA polymerase transcription factors, cytoskeletal proteins, nuclear pore proteins, neurofilaments, and oncogene products (5). Also, cytosolic proteins from Leishmania (21) and viral proteins (22, 23) have been shown to carry O-linked GlcNAc.

The fact that O-GlcNAc monosubstituted serine and threonine residues are frequently found in cytosolic and nuclear proteins means that peptides derived from the cytosolic degradation of these proteins could enter the MHC class I presentation pathway (1). Recognition of glycosylated peptides (and other posttranslational modifications) could therefore be of significant importance in immunity towards malignant diseases and in viral infections. In addition, it is possible that the acquisition or loss of glycosylation might provide a novel strategy for viruses or malignantly transformed cells to escape from selection pressure by CTL (24, 25), which does not depend on a mutation at the gene level. Furthermore, the loss or acquisition of oligosaccharide residues in endogenously presented peptides could lead to the formation of neoantigens, loss of tolerance, and development of autoimmunity.

The relevance of studying T cell responses to posttranslational modifications such as glycosylation now depends on the identification of a naturally occurring epitope of this kind. This potentially new group of peptide epitope determinants

![Figure 4. Peptide specificity and MHC restriction of CTL clones. T cell clones against peptides K3-O-GlcNAc (a and b) or K3 (c) obtained by limiting dilution were tested in CTL assays against T2-Kb (open) or T2-Db (closed) sensitized with 10 μM peptide K3-O-GlcNAc (circle), K3 (box), or without peptide (triangle). The Kb-restricted clone K3G.9 (a) was also tested against K1-N-GlcNAc (diamond).](image)

![Figure 5. CTL clones recognize K3-O-GlcNAc but not K3-O-GalNAc. The CTL clone K3G.4 was tested against T2-Db target cells sensitized with K3-O-GlcNAc (circle), K3-O-GalNAc (diamond), K3 (box), or without peptide (triangle).](image)
would so far have eluded discovery for technical reasons, since T cell epitope mapping conventionally has been achieved using synthetic peptides. The isolation of glycopeptides covalently linked with MHC class I molecules would be another approach to identifying this kind of epitope. The fact that no glycopeptides have so far been detected amongst the pool of peptides eluted from MHC class I could simply reflect the technical difficulties encountered in detecting O-GlcNAc modifications by Edman degradation and mass spectroscopy, even when they are specifically looked for (26). Indeed, using techniques specific for the detection of carbohydrate modifications, we have obtained preliminary data supporting the presence of O-GlcNAc modified peptides amongst the pool of peptides eluted from human spleen class I MHC (Haurum, J.S., unpublished observations).

Furthermore, glycopeptides might only comprise a small fraction of the peptides presented by MHC. This would not detract from their potential significance, since the relative abundance of individual peptides presented on the cell surface does not correlate with their importance as T cell antigens. Several immunodominant antigens have thus been extremely difficult to isolate from antigen-presenting cells in amounts sufficient for sequence analysis (27).

The subcellular location of the cytosolic glycosylation with O-linked GlcNAc could yield glycopeptides that are capable of entering the MHC class I presentation pathway. Our study shows that O-GlcNAc substitution is a promising candidate for a naturally occurring type of glycosylation capable of being recognized by CTL in an MHC-restricted way.

We wish to thank Dr. Elena Sadovnikova and Dr. Hans J. Stauss (Imperial Cancer Research Foundation, London, UK) for their valuable help with raising antipeptide CTLs; and Professor Jens Chr. Jensenius (University of Aarhus, Denmark) for helpful discussions.

J. S. Haurum is a Carlsberg-Wellcome Travelling Research Fellow, G. Asequell is an EC Fellow, and A. C. Lellouch is supported by a United States Public Health Service National Research Service Award F32 GM15811. This work was supported by the Carlsberg Foundation, the Wellcome trust, the Beckett Foundation, and Statens Sundhedsvidenskabelige Forskningsråd, Denmark.

Address correspondence to Dr. John S. Haurum, Molecular Immunology Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK.

Received for publication 14 March 1994 and in revised form 2 May 1994.

References

1. Germain, R.N. 1994. MHC-dependent antigen processing and peptide presentation: providing ligands for T-lymphocyte activation. Cell. 76:287.
2. Elliott, T., M. Smith, P. Driscoll, and A. McMichael. 1993. Peptide selection by class I molecules of the major histocompatibility complex. Curr. Biol. 3:854.
3. von Bonin, A., B. Ortmann, S. Martin, and H.U. Weltzien. 1992. Peptide-conjugated hapten groups are the major antigenic determinants for trinitrophenyl-specific cytotoxic T cells. Int. Immunol. 4:869.
4. Holt, G.D., and G.W. Hart. 1986. The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J. Biol. Chem. 261:8049.
5. Haltiwanger, R.S., W.G. Kelly, E.P. Roquemore, M.A. Blomberg, L.Y. Dong, L. Kreppel, T.Y. Chou, and G.W. Hart. 1992. Glycosylation of nuclear and cytoplasmic proteins is ubiquitous and dynamic. Biochem. Soc. Trans. 20:264.
6. Ohlen, C., J. Bastin, H.G. Ljunggren, S. Imreh, G. Klein, A.R. Townsend, and K. Kärre. 1990. Restoration of H-2Kb expression and processing of endogenous antigens in the MHC class I pathway by fusion of a lymphoma mutant to L cells of the H-2k haplotype. Eur. J. Immunol. 20:1873.
7. Salter, R.D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant Tbx cell hybrid. EMBO (Eur. Mol. Biol. Organ.) J. 5:943.
8. Hammerling, G.J., E. Rusch, N. Tada, S. Kimura, and U. Hammerling. 1982. Localisation of allodeterminants on H-2Kb antigens determined with monoclonal antibodies and H-2 mu- tant mice. Proc. Natl. Acad. Sci. USA. 79:4737.
9. Hammerling, G.J., U. Hammerling, and H. Lemke. 1979. Isolation of twelve monoclonal antibodies against Ia and H-2 antigens. Serological characterisation and reactivity with B and T lymphocytes. Immunogenetics. 8:433.
10. Lemieux, R.U., and R.M. Ratcliffe. 1979. The azidonitration of tri-O-acetyl D-galactal. Can. J. Chem. 57:1244.
11. Bielfeldt, T., S. Peters, M. Meldal, K. Bock, and H. Paulsen. 1992. A new strategy for the solid-phase synthesis of O-glycopeptides. Angew. Chem. Int. Ed. Engl. 31:857.
12. Elvin, J., C. Potter, T. Elliott, V. Cerundolo, and A. Townsend. 1993. A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. J. Immunol. Methods. 158:161.
13. Stauss, H.J., H. Davies, E. Sadovnikova, B. Chain, N. Horowitz, and C. Sinclair. 1992. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA. 89:7571.
14. Ljunggren, H.G., N.J. Stam, C. Ohlen, J.J. Neefjes, P. Hoglund, M.T. Heemels, J. Bastin, T.N. Schumacher, A. Townsend, K. Kärre, and H. Ploegh. 1990. Empty MHC class I molecules come out in the cold. Nature (Lond.). 346:476.
15. Kast, W.M., L. Roux, J. Curren, H.J. Blom, A.C. Voorouw, R.H. Meloen, D. Kolakofsky, and C.J. Melief. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. *Proc. Natl. Acad. Sci. USA.* 88:2283.

16. Schumacher, T.N., M.L. De Bruijn, L.N. Vernie, W.M. Kast, C.J. Melief, J.J. Neefjes, and H.L. Ploegh. 1991. Peptide selection by MHC class I molecules. *Nature (Lond.)* 350:703.

17. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H.G. Ram-mensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature (Lond.)* 351:290.

18. Fremont, D.H., M. Matsumura, E.A. Stura, P.A. Peterson, and I.A. Wilson. 1992. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. *Science (Wash. DC).* 257:919.

19. Ishioka, G.Y., A.G. Lamont, D. Thomson, N. Bulbow, F.C. Gaeta, A. Sette, and H.M. Grey. 1992. MHC interaction and T cell recognition of carbohydrates and glycopeptides. *J. Immunol.* 148:2446.

20. Harding, C.J., J. Kihlberg, M. Elofsson, G. Magnusson, and E.R. Unanue. 1993. Glycopeptides bind MHC molecules and elicit specific T cell responses. *J. Immunol.* 151:2419.

21. Handman, E., L.D. Barnett, A.H. Osborn, J.W. Goding, and P.J. Murray. 1993. Identification, characterisation and genomic cloning of an O-linked N-acetylgalactosamine-containing cytoplasmic Leishmania glycoprotein. *Mol. Biochem. Parasitol.* 62:61.

22. Benko, D.M., R.S. Haltiwanger, G.W. Hart, and W. Gibson. 1988. Virion basic phosphoprotein from human cytomegalovirus contains O-linked N-acetylgalactosamine. *Proc. Natl. Acad. Sci. USA.* 85:2573.

23. Caillet-Boudin, M.L., G. Strecker, and J.C. Michalski. 1989. O-linked GlcNAc in serotype-2 adenovirus fibre. *Eur. J. Biochem.* 184:205.

24. Phillips, R.E., S. Rowland-Jones, D.F. Nixon, F.M. Gotch, J.P. Edwards, A.O. Ogunesi, J.G. Elvin, J.A. Rothbard, C.R. Bangham, C.R. Rizza, and A.J. McMichael. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. *Nature (Lond.)* 354:453.

25. Masucci, M.G., Q.J. Zhang, R. Gavioli, P.O. De Campos, R.J. Murray, J. Brooks, H. Griffin, H. Ploegh, and A.B. Rickinson. 1992. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells. *Int. Immunol.* 4:1283.

26. Reason, A.J., H.R. Morris, M. Panico, R. Marais, R.H. Treisman, R.S. Haltiwanger, G.W. Hart, W.G. Kelly, and A. Dell. 1992. Localization of O-GlcNAc modification on the serum response transcription factor. *J. Biol. Chem.* 267:16911.

27. Udaka, K., T.J. Tsomides, and H.N. Eisen. 1992. A naturally occurring peptide recognized by alloreactive CD8 + cytotoxic T lymphocytes in association with a class I MHC protein. *Cell.* 69:989.